Cancer biology often feels like a badly managed renovation: knock down one wall, and a hidden crawlspace appears full of wiring nobody warned you about. That is more or less the vibe of a new Cancer Cell paper on lung cancer, where researchers found that after EGFR-targeted drugs push tumors into a...
That, in plain English, is the delightful plot twist in a new Gut paper on pancreatic cancer. The study looked at cancer-associated fibroblasts, or CAFs - cells in and around tumors that have a reputation a bit like raccoons in the attic: always present, usually blamed, and surprisingly complicated...
A new letter in European Urology by Edoardo Francini responds to the final overall survival results from the EORTC 1333/PEACE-3 trial, which tested enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer, or mCRPC for short - because oncology apparently believes every...
The weird trick here is that to study leukemia inside the human body, scientists built something outside the human body that behaves more like the human body than many of our usual stand-ins.
Sometimes the best cancer treatment idea is not “hit harder,” but “stop letting the tumor hide behind the curtains.” That is the tidy little trick at the heart of this new TROPHAMET trial: pair a familiar chemotherapy, methotrexate, with an immune checkpoint drug, avelumab, and see whether the...
Breaking news from the prostate cancer front: the tiny imaging underdog with a radioactive name tag may have just saved a lot of men from an unnecessary biopsy.
Biological pathways are supposed to work like plumbing: block the pipe upstream, and everything downstream dries up nicely, preferably while the scientist nods in a clean lab coat and nobody has to say “chromatin architecture” before dinner.
Meanwhile, in the colon - that long, underappreciated hallway of your digestive tract - geography is apparently doing some very rude things. A new CDC QuickStats report maps age-adjusted colorectal cancer death rates by state in 2024, and the big takeaway is not subtle: where you live in the United...
That is basically the bet behind a new Nature Nanotechnology paper on liver cancer - and the data suggest it may be a smart one. Instead of trying to kill tumor cells with one more blunt drug, the researchers built a nanoparticle system that selectively degrades a protein called CD147 inside liver...
A decent recipe needs the right ingredients, the timing has to behave, and somebody has to notice when the oven is lying. Glioblastoma treatment works a bit like that - you can bring in an immune checkpoint drug that looks terrific on paper, but if the tumor’s internal pantry is stocked with the...
If immune cells need training like gym regulars, prostate tumors have been the shady fitness center that keeps canceling the membership of the people supposed to do the spotting. This new paper asks a sneaky question: what if the problem is not that T cells are lazy, but that cancer has hidden the...
Cancer treatment sometimes feels less like bulldozing a field and more like yanking a few ugly weeds while hoping the rest of the garden behaves itself for another season. That is basically the promise of stereotactic body radiation therapy, or SBRT, in oligoprogressive prostate cancer - a phrase...
Cancer loves a good disguise. If the immune system is your body’s security team, tumors spend an absurd amount of energy forging badges, cutting camera feeds, and bribing the night guard. This new paper in Science Immunology points to one more trick in the playbook: a protein called DDX6 helps...
Molecular biology can look a lot like dating - proteins flirt, cells ghost each other, and sometimes one tissue ages like it just got dumped while another is somehow still using retinol and sleeping eight hours a night.
Archaeologists brush away dirt to figure out who ran the old city, and this colorectal cancer paper does something oddly similar - except the buried artifacts are immune cells, the ruins are tumour-draining lymph nodes, and the suspicious clue sitting in the middle of it all is a molecule called...
For years, the basic arrangement in advanced EGFR-mutated non-small-cell lung cancer has looked fairly tidy. Find the EGFR mutation, prescribe a modern EGFR inhibitor, and let the targeted drug do its elegant work. It is a pleasing architectural plan - precise, efficient, almost minimalist. Then...
That is the basic plot twist from a new Journal of Hepatology study on hepatocellular carcinoma, the most common form of liver cancer. The treatment in question - atezolizumab plus bevacizumab - is the current first-line celebrity duo for many patients with advanced disease. Think of it as the...
Glioblastoma is the meanest regular customer in brain cancer. It grows fast, returns often, and treats most therapies like spam email. Even when a treatment lands a punch, the tumor tends to stand back up and ask if that's all you've got.
Body weight and cancer risk have been playing poker together for years, but this new paper suggests the deck may be stacked across more cancer types than we realized. Not in a spooky "everything causes everything" way - more in a "well, that is an uncomfortably large pile of chips" way.
Cancer is a sneaky saboteur. It slips into your body's security network, steals a badge, and convinces part of the emergency response team to start locking the exits instead of chasing the intruder. That, in a nutshell, is the weird little drama at the heart of a new Immunity paper on neutrophils,...